Spots Global Cancer Trial Database for Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Official Title: Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Study ID: NCT00630110
Conditions
Study Description
Brief Summary: This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues.
Detailed Description: This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues. There are indications of advantages in combining vascular disrupting agents with standard agents in the treatment of advanced non-small cell lung cancer (NSCLC).
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic, Scottsdale, Arizona, United States
San Diego Pacific Oncology & Hematology Associates, Encinitas, California, United States
University San Diego Moores Cancer Center, San Diego, California, United States
Kaiser Permanente, San Diego, California, United States
Premiere Oncology, Santa Monica, California, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
University Texas Health Science Center at San Antonio (CTRC), San Antonio, Texas, United States
Policlinica Privada Instituto de Medicina Nuclear, Bahia Blanca, , Argentina
Hospital Britanico, Capital Federal, , Argentina
Instituto Oncologico De Cordoba, Cordoba, , Argentina
Clinica Universitaria Privada Reina Fabiola, Cordoba, , Argentina
Caici Centro de Asistencia e Investigacion Clinica Integral, Rosario, , Argentina
Hospital del Centrenario, Rosario, , Argentina
Mater Adult Hospital, South Brisbane, Queensland, Australia
Bendigo Health Care Group, Bendigo, Victoria, Australia
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Fundacap Pip XII Hospital do Cancer de Barretos, Barretos, , Brazil
Hospital Erasto Gaertner Liga do Combate as Cancer, Curitiba, , Brazil
Associacao Hospital de Caridade Ijui, Ijui, , Brazil
Hospital Sao Lucas, Porte Alegre, , Brazil
Hospital de clinicas de Porto Alegre, Porto Alegre, , Brazil
Clinionco-Clinica de Oncologia de Porto Alegre, Porto Alegre, , Brazil
Hosp.das Clinicas da Univ.de Sao Paulo, Sao Paulo, , Brazil
Instituto do Cancer Aenaldo Vieira de Carvahlo, Sao Paulo, , Brazil
Instituto Nacional del Cancer Oncology, Santiago, , Chile
Hospital Carlos Van Buren, Valparaiso, , Chile
Chittaranjan National Cancer Institute, Kolkata, W. Bengal, India
Kidwai Memorial Institute of Oncology, Bangalore, , India
Apollo Speciality Hospital, Chennai, , India
Apollo Hospital, Hyderabad, , India
SEAROC Cancer Centre S.K. Soni Hospital, Jaipur, , India
Subodh Mitra Cancer Hospital & Research Centre, Kolkata, , India
Tata Memorial Hospital, Mumbai, , India
Ruby Hall Clinic, Pune, , India
Andhra Medical College, Vishakhapatnam, , India
Contact Details
Name: Matthew A Spear, MD
Affiliation: Chief Medical Officer, Nereus Pharmaceuticals, Inc
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
